Side-by-side
| Feature | Genicular nerve RFA | GAE |
|---|---|---|
| Target | Sensory nerve branches around the knee | Abnormal small-vessel blood flow around inflamed synovium |
| Specialist | Interventional pain physician, anesthesiologist, or physiatrist with image-guided expertise | Interventional radiologist with embolization expertise |
| Typical pathway | Often includes a diagnostic nerve block | Angiography identifies target vessels during the procedure |
| What it changes | Pain signaling | Periarticular hypervascularity; proposed effect on inflammation |
| What it does not change | Cartilage loss, alignment, instability, or bone-on-bone mechanics | Cartilage loss, alignment, instability, or bone-on-bone mechanics |
| Evidence signal | Some positive trials; recent review found modest short-term benefit and uncertain durability | Promising uncontrolled studies; sham-controlled trials have not consistently shown benefit beyond sham |
| Coverage | Varies by policy; prior authorization may be required | Often limited or investigational |
What the evidence actually says
Older RFA trials reported pain and function improvements compared with injections, and major guidelines acknowledge a possible role. A 2025 review focused on randomized evidence found low-to-very-low certainty, modest short-term pain benefit, uncertain durability, and no consistent functional improvement.
GAE evidence is less settled. Early single-arm studies reported improvement, but sham-controlled studies have produced conflicting or negative results. A 2026 follow-up of 58 randomized patients with mild-to-moderate osteoarthritis found improvement in both GAE and sham groups, without a statistically significant between-group difference at 12 months.
Who might still discuss RFA?
- Someone with confirmed knee osteoarthritis and limiting pain despite appropriate conservative care.
- Someone not ready for, not wanting, or not medically suitable for replacement.
- A patient who understands that pain may improve temporarily while the arthritis remains unchanged.
Who might still discuss GAE?
- Someone considering an emerging option after standard nonsurgical treatments have not provided acceptable relief.
- A patient who understands the negative and conflicting sham-controlled evidence.
- Someone evaluated by an interventional radiologist who can explain selection, nontarget embolization risk, and whether a trial or registry is available.
Are these alternatives to replacement?
They can be alternatives to immediate surgery for symptom management, especially when surgery is unwanted or medically unsuitable. They are not biologic replacements for joint replacement: neither corrects damaged joint surfaces, deformity, or instability.
KneeLife standard: KneeLife will list GAE and RFA providers only after objective verification. Payment will never change the evidence summary, candidacy criteria, or organic ordering.